RecruitingNot ApplicableNCT07288983

PENG Block vs Suprainguinal FICB vs Lumbar ESPB for Analgesia After Hip Surgery

A Randomized, Double-Blinded, Controlled Trial Comparing the Analgesic Efficacy and Motor-Sparing Properties of the Pericapsular Nerve Group (PENG) Block, Suprainguinal Fascia Iliaca Compartment Block (S-FICB), and Lumbar Erector Spinae Plane Block (L-ESPB) in Patients Undergoing Hip Arthroplasty

Sponsor

Poznan University of Medical Sciences

Enrollment

93 participants

Start Date

Feb 6, 2026

Study Type

INTERVENTIONAL

Conditions

hip osteoarthritis

Summary

This randomized, double-blinded, controlled clinical trial compares three motor-sparing regional anesthesia techniques used for postoperative analgesia in patients undergoing hip arthroplasty: the Pericapsular Nerve Group (PENG) block, the suprainguinal Fascia Iliaca Compartment Block (S-FICB), and the Lumbar Erector Spinae Plane Block (L-ESPB). Although all three techniques are widely used in modern hip surgery, their relative analgesic efficacy, opioid-sparing potential, and impact on early functional recovery have not been directly compared in a single study. The primary objective is to determine which block provides the most effective postoperative analgesia while preserving motor function and facilitating early mobilization. Secondary objectives include comparisons of opioid consumption, pain scores at rest and during movement, time to first rescue analgesia, block-related adverse events, quadriceps strength, incidence of postoperative nausea and vomiting, and early functional outcomes. This study aims to identify the optimal motor-sparing regional anesthesia strategy for older adults undergoing hip arthroplasty.

Eligibility

Min Age: 65 YearsMax Age: 100 Years

Inclusion Criteria5

Adults aged 65 years or older scheduled to undergo elective hip arthroplasty under spinal anesthesia.
Ability to provide written informed consent.
Ability to understand and reliably use numerical pain assessment tools (NRS 0-10).
ASA physical status II-III.
Expected postoperative hospitalization of at least 48 hours to ensure complete data collection.

Exclusion Criteria12

Inability to provide informed consent due to cognitive impairment, language barrier, or severe hearing/speech limitations.
Coagulopathy or therapeutic anticoagulation not meeting safety criteria for regional anesthesia.
Local infection at the planned block site.
Allergy, hypersensitivity, or contraindication to ropivacaine, local anesthetics, or study medications.
Pre-existing lower-limb neurological deficits (motor or sensory) affecting outcome assessments.
Severe spinal deformity or anatomical limitations preventing safe performance of regional blocks.
Chronic opioid use (defined as >30 mg oral morphine equivalents daily for more than 2 weeks).
Severe renal failure (eGFR <30 mL/min/1.73m²) or severe hepatic impairment.
Uncontrolled diabetes mellitus (fasting glucose >300 mg/dL or HbA1c >10%).
History of local anesthetic systemic toxicity (LAST).
Participation in another interventional clinical trial within the past 30 days.
Any condition deemed by investigators to interfere with protocol adherence, safety monitoring, or outcome reliability.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREPericapsular Nerve Group (PENG) Block

The Pericapsular Nerve Group (PENG) block will be performed under ultrasound guidance using a curvilinear or linear transducer. A 22-gauge echogenic needle will be advanced in-plane toward the fascial plane between the iliopsoas tendon and the pelvic brim at the level of the anterior inferior iliac spine. A total of 20 mL of 0.2% ropivacaine will be injected incrementally with repeated aspiration to avoid intravascular injection. No additional peripheral nerve blocks will be performed. All patients will receive standardized spinal anesthesia and multimodal postoperative analgesia.

PROCEDURESuprainguinal Fascia Iliaca Compartment Block (S-FICB)

The suprainguinal fascia iliaca compartment block will be performed under ultrasound guidance using a high-frequency linear probe placed in the sagittal oblique plane above the inguinal ligament. After identifying the fascia iliaca above the iliacus muscle, a 22-gauge echogenic needle will be advanced in-plane into the suprainguinal fascia iliaca space. A total of 30 mL of 0.2% ropivacaine will be injected to achieve cranial spread toward the femoral nerve, lateral femoral cutaneous nerve, and obturator nerve. All patients will receive standardized spinal anesthesia and multimodal postoperative analgesia.

PROCEDURELumbar Erector Spinae Plane Block (L-ESPB)

The lumbar erector spinae plane block will be performed under ultrasound guidance at the L4 transverse process level. A curvilinear or linear ultrasound probe will be used to identify the erector spinae muscle and underlying transverse process. A 22-gauge echogenic needle will be inserted in-plane and advanced to the fascial plane deep to the erector spinae muscle and superficial to the transverse process. A total of 20 mL of 0.2% ropivacaine will be injected incrementally. No sacral ESPB will be added. All patients will receive standardized spinal anesthesia and multimodal postoperative analgesia.